Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RVMD · as of Sep 30, 2025
Ownership Breakdown
341
Institutional Holders
▲ 18 vs Q2
$8.96B
Total Inst. Value
▲ $1.94B vs Q2
212.60M
Shares Outstanding
freeFloat 89.54%
191.95M
13F Shares Held
▲ 1.22M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RVMD largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 15.66M | 8.32% | 8.32% | $731.47B | Nov 7, 2025 | ▼ 98.6K |
FARALLON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 14.63M | 7.77% | 7.77% | $683.02B | Feb 17, 2026 | ▲ 300.0K |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 11.36M | 6.04% | 6.04% | $530.31B | Nov 14, 2025 | ▲ 765.3K |
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 9.81M | 5.22% | 5.22% | $458.29B | Nov 14, 2025 | ▼ 446.3K |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 9.46M | 5.03% | 5.03% | $441.57B | Nov 14, 2025 | ▲ 90.4K |
FMR LLC biological products, (no diagnostic substances) | 9.40M | 5.00% | 5.00% | $439.06B | Nov 13, 2025 | ▲ 1.08M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 8.33M | 4.43% | 4.43% | $388.91B | Nov 12, 2025 | ▼ 333.6K |
NEXTECH INVEST, LTD. biological products, (no diagnostic substances) | 7.60M | 4.04% | 4.04% | $354.97B | Nov 14, 2025 | — held |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 6.22M | 3.31% | 3.31% | $290.63B | Nov 14, 2025 | ▲ 130.0K |
BELLEVUE GROUP AG biological products, (no diagnostic substances) | 5.57M | 2.96% | 2.96% | $260.30B | Nov 14, 2025 | ▲ 994.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+9.90M shares2
New Positions
first time holders14
Decreased
−6.11M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.79M
+9.90M / −6.11M
Net new holders
+17
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RVMD insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
11
Sell transactions
0.36
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Mancini Anthony See Remarks | May 26, 2026 | Sale | 700 | $153.30 | $107.3K | 56.8K | Form 4 ↗ |
Mancini Anthony See Remarks | May 26, 2026 | Sale | 2,000 | $154.06 | $308.1K | 54.8K | Form 4 ↗ |
Mancini Anthony See Remarks | May 26, 2026 | Sale | 421 | $154.82 | $65.2K | 54.4K | Form 4 ↗ |
Mancini Anthony See Remarks | Apr 27, 2026 | Sale | 1,671 | $131.66 | $220.0K | 55.8K | Form 4 ↗ |
Mancini Anthony See Remarks | Apr 27, 2026 | Sale | 1,049 | $132.88 | $139.4K | 54.8K | Form 4 ↗ |
Mancini Anthony See Remarks | Apr 27, 2026 | Sale | 400 | $134.34 | $53.7K | 54.4K | Form 4 ↗ |
GOLDSMITH MARK A See Remarks | Apr 15, 2026 | Sale | 120,000 | $150.09 | $18.01M | 276.7K | Form 4 ↗ |
Mancini Anthony See Remarks | Mar 25, 2026 | Sale | 1,800 | $93.22 | $167.8K | 90.0K | Form 4 ↗ |
Mancini Anthony See Remarks | Mar 25, 2026 | Sale | 3,128 | $94.16 | $294.5K | 86.9K | Form 4 ↗ |
Mancini Anthony See Remarks | Mar 25, 2026 | Sale | 21,086 | $95.49 | $2.01M | 65.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Revolution Medicines, Inc. (RVMD) is primarily owned by institutional investors, who hold approximately 90.3% of total shares outstanding. Company insiders own approximately 10.46%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Revolution Medicines, Inc. is VANGUARD GROUP INC, holding approximately 15.66 million shares — equal to 8.32% of outstanding shares — as of September 30, 2025.
A total of 341 institutional investors currently hold RVMD stock, with a combined institutional value of approximately $8.96 billion as of the most recent 13F filing period.
Frequently asked questions
RVMD ownershipRevolution Medicines, Inc. (RVMD) is primarily owned by institutional investors, who hold approximately 90.3% of shares. The largest shareholder is VANGUARD GROUP INC with a 8.32% stake. Company insiders hold 10.46%. Data sourced from SEC Form 13F as of September 30, 2025.